NNOX:NASDAQNANO-X IMAGING LTD Analysis

Technical snapshot: NNOX trades at $2.85, sitting just below the 20‑day SMA of $2.40 and well under the 200‑day SMA of $3.50, indicating a bearish longer‑term trend. Momentum is mixed – the RSI sits at 69.5 (near overbought), while the MACD line (+0.039) is above its signal (‑0.022) generating a bullish histogram (+0.062). Volatility is elevated at >50% 30‑day and beta spikes at 1.83, suggesting price swings will likely outpace the market. Valuation signals show a price‑to‑book of 1.19, a price‑to‑sales of 16.1, and a negative forward P/E (‑9.34) due to losses, yet the upside/downside metric of +160% versus a median analyst target of $7 points to substantial upside potential.
Fundamentals & news catalyst: The company reports a 13.7% revenue growth year‑over‑year but continues to post deep negative gross (‑98%) and operating margins, with a cash balance of $45.2M offset by $7.9M debt (high D/E of 5.0). Recent material news includes a new U.S. distribution agreement, a regional partnership expanding outpatient coverage in the Midwest, a Zacks Rank 2 “Buy” upgrade, and a clinical collaboration with Meir Medical Center, all of which could accelerate adoption of the Nanox.ARC platform and improve the earnings outlook.